MOUNTAIN VIEW, Calif., May 11 /PRNewswire/ -- Aviron (Nasdaq: AVIR) today
announced the promotion of Edward J. Arcuri, Ph.D. to senior vice president,
operations. In this newly created position, Dr. Arcuri will oversee
operations, product development and manufacturing.
Dr. Arcuri joined Aviron in July 1999 as vice president, manufacturing,
responsible for all FluMist(TM) manufacturing activities at Aviron's contract
manufacturer, Celltech Medeva, the international pharmaceutical marketing arm
of the Celltech Group plc, in Speke, England, and at Aviron's facilities in
Philadelphia and Mountain View. FluMist(TM) is Aviron's investigational
intranasal influenza vaccine.
"Since joining Aviron last July, Ed has provided extraordinary leadership
to the team solidifying our manufacturing infrastructure for a targeted
submission of a Biologics License Application for FluMist(TM) during the
fourth quarter. His promotion reflects our substantial progress in
manufacturing," said C. Boyd Clarke, Aviron president and chief executive
officer.
Prior to joining Aviron, Dr. Arcuri served as vice president,
manufacturing operations and process development at North American Vaccine
Inc., where he was responsible for all phases of vaccine manufacturing,
including bulk manufacturing, filling and packaging. Before joining North
American Vaccine, Dr. Arcuri was senior director, biological manufacturing at
Merck and Co., where he was responsible for manufacturing licensed bulk
biologicals, including vaccines for bacterial meningitis, hepatitis B,
pneumonia, measles, mumps, rubella (MMR) and varicella (chicken pox). Prior
to joining Merck, he held several research and development (R&D) management
positions at SmithKline Beecham.
Dr. Arcuri earned a bachelor's degree in biology from the State University
of New York at Albany and a master's degree and a Ph.D. in biology from
Rensselaer Polytechnic Institute.
Aviron is a biopharmaceutical company based in Mountain View, California,
focused on the prevention of disease through innovative vaccine technology.
Actual results may differ materially from the forward-looking statements
contained in this release. Factors that could cause actual results to differ
include, but are not limited to, failure to validate the manufacturing
process, facilities or equipment for the company's nasal influenza vaccine,
and the assessment by regulatory agencies that the company's future license
applications for its nasal influenza vaccine are incomplete or inadequate to
approve the product for marketing to one or more target populations.
Additional information concerning factors that could cause such a difference
is contained in Aviron's SEC filings, including its Annual Report on Form 10-K
for the year ended December 31, 1999.
To receive an index and copies of recent press releases, call Aviron's
News-On-Call toll-free fax service, 800-758-5804, extension 114000.
Additional information about the company can be located at
http://www.aviron.com .
SOURCE Aviron
 back to top
Related links:
http://www.aviron.com
Company News On-Call:
http://www.prnewswire.com/comp/114000.html or fax,
800-758-5804, ext. 114000
CONTACT:
media, John Bluth of Aviron, 650-919-3716; or
Claudette Hibbert of Fleishman-Hillard, 212-453-2000, for Aviron;
or investors, John Bluth, 650-919-3716, or Fred Kurland,
650-919-6666, both of Aviron
|
